Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Inovio Pharmaceuticals Popped Today

By Maxx Chatsko - Feb 18, 2020 at 1:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical company received a lot of positive media attention over the weekend.

What happened

Shares of Inovio Pharmaceuticals (INO 0.52%) rose nearly 10% today after the company received an abundance of favorable media coverage over the weekend. In an interview with Yahoo Finance's On the Move, CEO Joseph Kim said the company had developed its experimental vaccine against the novel coronavirus strain hours after receiving the genetic sequence of the virus. 

That news was amplified by various local and national media outlets. For instance, the Los Angeles Times ran a story with a headline, "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". 

The gains quickly dissipated, however. As of 1:08 p.m. EST, the pharma stock had settled to a 1% gain.

A scientist looking through a microscope.

Image source: Getty Images.

So what

The revelation that Inovio Pharmaceuticals needed only hours to design its vaccine candidate against the coronavirus strain known as SARS-CoV-2, which causes a respiratory illness named COVID-19, is impressive. It helps that SARS-CoV-2 shares roughly 80% of its genetic sequence with other known coronavirus strains, which the company had worked on vaccines for in the past. 

The news is also a reminder of the fast pace of innovation in biology-based technologies. Advances in genetic sequencing, machine learning, and DNA synthesis should combine to rapidly reduce the time to design new vaccine and drug candidates. 

Of course, design is only one part of drug development. Animal- and human-testing will still be a bottleneck, as there's not much that can be done to expedite the time to generate safety and efficacy results of a novel vaccine candidate. That said, it's possible for the global pharmaceutical industry to make a vaccine available by the end of 2020 -- just in time to respond to a potential second wave of circulation.

Now what

Despite the opportunistic efforts of the company, investors should be wary of Inovio Pharmaceuticals. The company hasn't lived up to lofty promises made in the past and was on pace to generate operating losses in excess of $100 million in 2019. It also faces stiff competition from much larger and more experienced vaccine developers such as Gilead Sciences and Sanofi

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.95 (0.52%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.